The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of the hypomethylating agent azacitadine with the nanoparticle albumin bound paclitaxel in the treatment of patients with advanced or metastatic solid tumors.
T. L. Dumlao
No relevant relationships to disclose
T. W. Butler
No relevant relationships to disclose
D. L. Dyess
No relevant relationships to disclose
H. T. Khong
Consultant or Advisory Role - Abraxis BioScience
Research Funding - Abraxis BioScience; Celgene